



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) Michele Aquilano
Address(es) 64, via Soccorso,71016, San Severo (FG), Italy
E-mail aquilanomichele@gmail.com
Nationality Italian
Date of birth 1992-08-13

Work Experience

Name and address of employer Mater Olbia Hospital, Olbia
Type of business or sector Radiation Oncology Department
Dates From 01/07/2022
Occupation or position held Radiation Oncologist

Name and address of employer IRCCS, Ospedale San Raffaele, Milan
Type of business or sector Medical Oncology Department
Dates From 01/03/2022 to 30/06/2022
Occupation or position held Medical Oncologist

Education

Occupation or position held Specialist in Radiation Oncology
Dates From 29/12/2021

Main activities and responsibilities Research Fellowship
Name and address of employer Erasmus Medical Center, Rotterdam
Type of business or sector Radiation Oncology
Dates From September to December 2021
Occupation or position held Research Fellowship

Main activities and responsibilities Doctor in training

| | |
|--|---|
| Name and address of employer | AOU Careggi, University Hospital of Florence |
| Type of business or sector | Radiation Oncology |
| Dates | From January 2018 to December 2021 |
| Occupation or position held | Specialist medical training |
| Main activities and responsibilities | Doctor in training |
| Name and address of employer | AOU Sassari, University Hospital of Sassari |
| Type of business or sector | Radiation Oncology |
| Dates | From 2017 December to 2018 December |
| Occupation or position held | Specialist medical training |
| Name and type of organisation providing education and training | University Hospital of Rome "La Sapienza" |
| Level in national or international classification | 1 st level degree in Biotechnologies Final degree mark: 107/110 |
| Date | Dissertation/thesis title: Vegetable substances and liver cancer: modulation molecular mechanisms in vitro for inhibit proliferation of human cholangiocarcinoma and liver cancer cells 07/17/2017 |

| | |
|--|---|
| Name and type of organisation providing education and training | Policlinico Universitario Umberto I, University Hospital of Rome "La Sapienza" |
| Level in national or international classification | Graduation in Medicine and Surgery Final degree mark: 110/110 Dissertation/thesis title: critical organs saving in intensity modulated radiotherapy: hearing evaluation in nasopharynx and oropharynx cancer radiotherapy treated |
| Date | 09/29/2016 |
| Title of qualification awarded | Member of Medical Association of Foggia, Italy. (Medical license number 7090) |
| Name and type of organisation providing education | Liceo Classico "Matteo-Tondi", San Severo (FG) |
| Level in national or international classification | Secondary school diploma: classical certificate |
| Date | 07/15/2010 |

P. Borghetti, J. Imbrescia, G. Volpi, V. Scotti, **M. Aquilano**, A. Bruni, D. Franceschini, S. Ursino, P. Ciammella, G. Piperno, M. Taraborrelli & S. M. Magrini Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC *Radiat Oncol* 17, 124 (2022). <https://doi.org/10.1186/s13014-022-02084-5>

G. Francolini, B. Detti, V. Di Cataldo, P. Garlatti, **M. Aquilano**, A. Allegra, S. Lucidi, C. Cerbai, L.P. Ciccone, V. Salvestrini, G. Stocchi, B. Guerrieri, L. Visani, M. Loi, I. Desideri, M. Mangoni, I. Meattini & L. Livi. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). *Radiol med* 127, 912–918 (2022). <https://doi.org/10.1007/s11547-022-01511-7>

G. Francolini, R. Campi, V. Di Cataldo, B. Detti, M. Loi, L. Triggiani, S. La Mattina, P. Borghetti, S. M. Magrini, L. Nicosia, F. Alongi, P. Ghirardelli, V. Vavassori, A. G. Allegra, **M. Aquilano**, E. Scoccimarro, A. Peruzzi, P. Pastina, L. Visani, I. Desideri, S. Serni, I. Meattini & L. Livi. Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience. *Clin Transl Oncol* (2022). <https://doi.org/10.1007/s12094-022-02844-5>

G. Francolini, M. Loi, L. P. Ciccone, B. Detti, V. Di Cataldo, P. Pinzani, F. Salvianti, G. Salvatore, M. Sottili, C. Santini, G. Frosini, L. Visani, L. Burchini, C. Mattioli, A. G. Allegra, M. Valzano, C. Cerbai, **M. Aquilano**, V. Salvestrini, I. Desideri, M. Mangoni, I. Meattini & L. Livi. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275). *Med Oncol* 39, 119 (2022). <https://doi.org/10.1007/s12032-022-01756-2>

G. Francolini, C. Cerbai, M. Loi, V. Di Cataldo, B. Detti, G. Simontacchi, L.P. Ciccone, L. Masi, R. Doro, A. Allegra, V. Salvestrini, C. Mattioli, G. Frosini, L. Burchini, **M. Aquilano**, G. Stocchi, I. Desideri, L. Livi. PD-0411 Predictive factors of late GU toxicity after Cyberknife re-irradiation for locally recurrent PCa Radiotherapy and Oncology S354, MAY 01, 2022 DOI:[https://doi.org/10.1016/S0167-8140\(22\)02846-8](https://doi.org/10.1016/S0167-8140(22)02846-8)

S. Lucidi, A. Romei, N. Bertini, M. Loi, P. Bonomo, I. Desideri, V. Di Cataldo, B. Detti, M. Casati, M. Zani, C. Arilli, V. Salvestrini, M. Roghi, **M. Aquilano**, M. Ganovelli, M. Banini, M. Valzano, C. Bellini, I. Meattini, L. Livi. PO-1299 Charlson Comorbidity Index for patients selection in definitive chemoradiation for anal carcinoma. Radiotherapy and Oncology S1096-S1097, MAY 01, 2022 DOI:[https://doi.org/10.1016/S0167-8140\(22\)03263-7](https://doi.org/10.1016/S0167-8140(22)03263-7)

G. Francolini, V. Di Cataldo, B. Detti, A. Allegra, L. Burchini, L.P. Ciccone, C. Cerbai, C. Mattioli, G. Frosini, B. Guerrieri, **M. Aquilano**, V. Salvestrini, A. Chiti, M. Sollini, G. Simontacchi, I. Desideri, L. Livi. PO-1363 Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914) May 01, 2022 Radiotherapy and Oncology DOI: [https://doi.org/10.1016/S0167-8140\(22\)03327-8](https://doi.org/10.1016/S0167-8140(22)03327-8)

M. Aquilano, M. Loi, L. Livi, J.J. Nuytens. PO-1261 Is SBRT an effective treatment in metastatic lung cancer with oligoprogressive disease? May 2022 Radiotherapy and Oncology 170:S1064-S1065 DOI: 10.1016/S0167-8140(22)03225-X

G. Francolini, B. Detti, V. Di Cataldo, S. Caini, A.R. Alitto, S. Parisi, C. Demofonti, A. Bruni, G. Ingrosso, G. Timon, A. Tagliagambe, **M. Aquilano**, L.P. Ciccone, V. Salvestrini, G. Frosini, C. Cerbai, A. Allegra, L. Burchini, I. Desideri, M. Mangoni, I. Meattini, L. Livi. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterone in mCPRC: ARTO trial May 01, 2022 Radiotherapy and Oncology DOI: [https://doi.org/10.1016/S0167-8140\(22\)02627-5](https://doi.org/10.1016/S0167-8140(22)02627-5)

M. Loi, I. Bononucci, L. Masi, R. Doro, G. Francolini, V. Di cataldo, P. Bonomo, L. Visani, M. Tempobono, N. Bellosi, S. Pazzaglini, M. Cassinelli, G. Simontacchi, D. Greto, I. Desideri, S. Lucidi, **M. Aquilano**, L. Livi. PO-1469 CT-Guided Fiducial Placement for Robotic Stereotactic Body Radiotherapy: Efficacy and Safety May 2022 Radiotherapy and Oncology 170:S1247-S1248 DOI: 10.1016/S0167-8140(22)03433-8

Olmetto E, Perna M, Cerbai C, **Aquilano M**, Banini M, Mariotti M, Livi L, Scotti V. A narrative review of postoperative adjuvant radiotherapy for non-small cell lung cancer. *Mediastinum*. 2022 Mar 25;6:4. doi: 10.21037/med-21-31. PMID: 35340837; PMCID: PMC8841548.

Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, Mattina S, D'Angelillo, R.M., Demofonti, C, Mazzola R, Cuccia F, Alongi F, **Aquilano M**, Allegra, A.G., Ciccone I.P, Burchini L, Salvestrini V, Morelli I, Livi L. (2021). Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis. *Clinical Oncology*. 10.1016/j.clon.2021.09.014.

Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V, **Aquilano M**, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi G, Ciccone L.P, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). *Clinical & Experimental Metastasis*. 38. 10.1007/s10585-021-10118-7.

Aquilano M, Salvatore G, Loi M, Greto D, Scoccimarro E, Ciccone L.P, Stocchi G, Salvestrini V, Santini C, Sottili M, Mangoni M, Livi L. PO-1921 Radiosensitizing effect of Trabectedin on human soft tissue sarcoma cells. 2021 Radiotherapy and Oncology S1638-S1639 [https://doi.org/10.1016/S0167-8140\(21\)08372-9](https://doi.org/10.1016/S0167-8140(21)08372-9)

Aquilano M, Lucidi S, Mauro L, Francolini G, Simontacchi G, Greto D, Desideri I, Bonomo P, Allegra A, Mariotti M, Masi L, Doro R, Bonucci I, Di Cataldo V, Mangoni M, Livi L. PO-1444 Determinants of radioresistance and progression-free interval in SBRT-treated spinal metastases. 2021 Radiotherapy and Oncology S1185-S1186 [https://doi.org/10.1016/S0167-8140\(21\)07895-6](https://doi.org/10.1016/S0167-8140(21)07895-6)

Scoccimarro E, Ciccone L.P, Caini S, **Aquilano M**, Peruzzi A, Becherini C, Livi L, Desideri I, Bonomo P. PO-0998 Dosimetric predictors of patient-reported taste alteration in head and neck cancer: a cohort study. 2021 Radiotherapy and Oncology S830-S831 [https://doi.org/10.1016/S0167-8140\(21\)07449-1](https://doi.org/10.1016/S0167-8140(21)07449-1)

Ciccone L.P, Zani M, Scoccimarro E, **Aquilano M**, Banini M, Caprara L, Mariotti M, Salvestrini M, Becherini C, Desideri I, Marrazzo L, Pallotta L, Livi L, Bonomo P. PO-0997 Lack of CTV_P2 is not associated with a detrimental outcome in oropharyngeal cancer: a cohort study. 2021 Radiotherapy and Oncology. S829-S830 [https://doi.org/10.1016/S0167-8140\(21\)07448-X](https://doi.org/10.1016/S0167-8140(21)07448-X).

Visani L, Ratosi I, Scoccimarro E, Becherini C, Saieva C, Desideri I, Scotti V, Ozarem M, Ribnikar D, **Aquilano M**, Cerbai C, Orzalesi L, Bernini M, Sanchez L, Nori J, Bianchi S, Meattini I, Livi L. OC-0071 Safety and efficacy of concomitant radiation and CDK4/6 inhibitors in breast cancer patients. 2021 Radiotherapy and Oncology. S44-S45 [https://doi.org/10.1016/S0167-8140\(21\)06765-7](https://doi.org/10.1016/S0167-8140(21)06765-7)

G. Francolini, M. Loi, V. Di Cataldo, B. Detti, G. Stocchi, A.G. Allegra, C. Bellini, **M. Aquilano**, L.P. Ciccone M. Mariotti, V. Salvestrini, E. Scoccimarro, M. Valzano, G. Simontacchi, P. Bonomo, S. Lucidi, I. Desideri, I. Meattini, L. Livi PO-1316 Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation. 2021 Radiotherapy and Oncology. S1080-S1081 [https://doi.org/10.1016/S0167-8140\(21\)07767-7](https://doi.org/10.1016/S0167-8140(21)07767-7)

G. Francolini, V. Di Cataldo, Detti B, Loi M, Ghirardelli P, Vavassori V, Nicosia L, Alongi F, Triggiani L, Mattina S, Allegra A.G., Scoccimarro E, **Aquilano M**, Lucidi S, Valzano M, Peruzzi A, Morelli I, Mariotti M, Salvestrini Viola, Livi L. (2021). PD-0849 Concomitant Nivolumab and RT in metastatic kidney cancer. Benefit of ablative vs palliative approach. *Radiotherapy and Oncology*. 161. S683. 10.1016/S0167-8140(21)07128-0.

G. Francolini, C. Bellini, V. Di Cataldo, B. Detti, Bruni A, Alicino G, Triggiani L, Mattina S, D'Angelillo R.M, Demofonti C, Mazzola R, Cuccia F, Alongi F, **Aquilano M**, Allegra, A.G., Ciccone L.P., Stocchi G, Salvestrini V, Guerrieri B, Livi, L. (2021). PO-1366 Pattern of recurrence after SBRT in prostate cancer patients with nodal pelvic relapse. *Radiotherapy and Oncology*. 161. S1120-S1121. 10.1016/S0167-8140(21)07817-8.

Aquilano M, Becherini C, Desideri I, Stocchi G, Banini M, Mariotti M, Simontacchi G, Livi L, Bonomo P. Cost analysis of topic interventions and Quality of life related to Radiation Dermatitis: EORTC QLQ-C30; QLQ-H&N43 and Skindex 29 outcomes. *Support Care Cancer* 29, 1–261 (2021). <https://doi.org/10.1007/s00520-021-06285-8>

Francolini G, Desideri I, Stocchi G, Ciccone L.P, Salvestrini V, Garlatti, P, **Aquilano M**, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi Gabriele, Livi L (2021). Impact of COVID-19 on workload burden of a complex radiotherapy facility. *La Radiologia medica*. DOI:10.1007/s11547-021-01338-8.

Francolini G, Garlatti P, Loi M, Detti B, **Aquilano M**, Allegra A, Guerrieri Barbara, Salvestrini V, Pinzani P, Bell. ini C, Salvianti F, Stocchi G, Ciccone L.P, Salvatore G, Sottili M, Di Cataldo V, Desideri I, Mangoni M, Meattini I, Livi L (2021). ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.. *Journal of Clinical Oncology*. 39. 118-118. DOI:10.1200/JCO.2021.39.6_suppl.118.

Visani L, Saieva C, Desideri I, Scotti V, Dominici L, Scoccimarro E, **Aquilano M**, Cerbai C, Palmieri V.E, Maragna V, Becherini C, Bernini M, Sanchez L, Orzalesi L, Nori J, Antonuzzo L, Bianchi S, Meattini I, Livi L. (2020). PO-0928: Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients.. *Radiotherapy and Oncology*. 152. S495-S496. DOI:10.1016/S0167-8140(21)00945-2.

Francolini G, Garlatti P, Detti B, Bruni A, Mantini G, Pergolizzi S, Borghetti P, D'Angelillo R.M, Alongi, F, Jereczek-Fossa B.A, Franzese C, Tagliagambe A, Di Cataldo V, **Aquilano M**, Mariotti M, Salvestrini V, Ciccone L.P, Stocchi G, Livi, L. (2020). Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719). *European Urology Open Science*. 21. S150. DOI:10.1016/S2666-1683(20)36207-8.

Mangoni M, Salvatore G, Greto D, Sottili M, Talamonti C, Lorenzetti V, **Aquilano M**, Peruzzi A, Salvestrini V, Visani L, Bonomo P, Scorianz M, Muratori F, Scoccianti G, Campanacci D, Livi L. (2020). PD-0067: An ex vivo assay to detect radiosensitization by PARP-inhibitors in soft tissue sarcomas. *Radiotherapy and Oncology*. 152. S28. DOI:10.1016/S0167-8140(21)00093-1.

Desideri I, Francolini G, Ciccone L.P, Stocchi G, Salvestrini V, **Aquilano M**, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L. (2020). Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. *Supportive Care in Cancer*. DOI:10.1007/s00520-020- 05793-3.

Ratosa, I, Scoccimarro E, Dominici L, Steinacher M, **Aquilano M**, Cerbai, C, Desideri I, Marinko T, Livi, L. Meattini I. (2020). Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer. *European Journal of Cancer*. 138. S66. DOI:10.1016/S0959-8049(20)30703-6.

Francolini G, Salvestrini V, Loi M, Mangoni M, Detti B, Pinzani P, Salvianti F, Desideri I, **Aquilano, M**, Mariotti M, Garlatti P, Stocchi G, Ciccone L.P, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. (2020). 617P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275). *Annals of Oncology*. 31. DOI:10.1016/j.annonc.2020.08.930.

Meattini I, Scoccimarro E, Saieva C, Desideri I, Visani L, Dominici L, Cerbai C, **Aquilano M**, Ciccone, L. P, Palmieri V, Scotti V, Nori J, Bernini M, Orzalesi L, Sanchez L, Dieci M, Bianchi S, Livi L. (2020). Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).. *Journal of Clinical Oncology*. 38. 562- 562. DOI:10.1200/JCO.2020.38.15_suppl.562.

Ratosa I, Scoccimarro E, Steinacher M, Dominici L, **Aquilano M**, Cerbai C, Desideri I, Ribnikar D, Marinko T, Livi L, Meattini I. (2020). Cyclin-dependent kinase 4/6 inhibitors combined with radiation therapy for patients with metastatic breast cancer. *Clinical Breast Cancer*. 20. DOI:10.1016/j.clbc.2020.05.013.

Francolini G, Loi M, Detti B, Mangoni M, Desideri I, Muntoni C, Ciccone L.P, **Aquilano M**, Pinzani P, Salvianti F, Lucidi S, Mariotti M, Garlatti P, Salvatore G, Sottili M, Livi L. (2020). Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.. *Journal of Clinical Oncology*. 38. 246-246. DOI:10.1200/JCO.2020.38.6_suppl.246.

Francolini G, Loi M, Detti B, Mangoni M, Desideri I, Muntoni C, Ciccone L.P, **Aquilano M**, Pinzani P, Salvianti F, Lucidi S, Mariotti M, Garlatti P, Salvatore G, Sottili M, Livi L. (2020). Poster ASCO GU Preliminary results of a prospective assessment of Androgen receptor splice variants in mCRPC patients undergoing Androgen Receptor Targeted Agents.

Dedola M.F, Masala F, **Aquilano M**, Pinna F, Soddu S (2019) Cardiac damage after radiotherapy for breast cancer: prevention prospects *Cardiologia Ambulatoriale – Outpatient cardiology* 1: 67-72
DOI: 10.17473/1971-6818-2019-1-6

Publications Submitted | Francolini G, Detti B, Di Cataldo V, Garlatti P, **Aquilano M**, Allegra A, Lucidi S, Cerbai C, Ciccone L.P, Salvestrini V, Stocchi G, Guerrieri B, Loi M, Desideri I, Mangoni M, Meattini I, Livi L. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719) (Submitted)

Borghetti P; Imbrescia. J; Volpi G; Scotti V; **Aquilano M**; Bruni A; Francheschini D; Ursino S; Ciammella P; Piperno G; Taraborelli M; Magrini S.M; Chemo-radiotherapy plus Durvalumab for loco-regional relapse of resected NSCLC (Submitted)

Aquilano M, Loi M , Visani L, Livi L, . Nuytens J.J Is SBRT an effective treatment in metastatic lung cancer with oligoprogressive disease? (Submitted)

MEETINGS

Abstracts/Poster or oral presentation

Aquilano M, Loi M, Livi L, J.J.Nuyttens. Is SBRT an effective treatment in metastatic lung cancer with oligoprogressive disease?, ESTRO CONGRESS 2022”

Picchetto A, Pronio A, Magliocca F.M., Choppin de Janvry E, **Aquilano M**, D'Ambrosio G Mappatura ex vivo dei linfonodi sentinella nei tumori colo-rettali tramite la fluorescenza vicina all'infrarosso e colorante vitale verde indocianina (Podium Presentation) (Roma) XVIII Congresso Nazionale della Società Italiana di Chirurgia Endoscopica SICE, Milano 28-29 Settembre 2017

Aquilano M, Barberio M., Ciccone L.P, Teriaca M.A, Garlatti P, Caramia G, Maragna V, Salvatore G, Mangoni M, Loi M, Greto D, Sottili M, Livi L. Enhancement of radiosensitivity of soft tissue sarcoma (sts) cells by trabectedin (Selected Oral Communications; BA4) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Garlatti P, Francolini G, Detti B, Bruni A, Mantini G, Pergolizzi S, Borghetti P, D'Angelillo R.M, Santoni R, Alongi F, Jereczek Fossa B.A, Franzese C, Tagliagambe A, Dicaldo V, **Aquilano M**, Mariotti M, Salvestrini V, Stocchi G, Livi L. Preliminary analysis from a Phase II randomized trial exploring ablative radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing treatment with abiraterone acetate (ARTO TRIAL NCT03449719) (Oral Communications CO016) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Stocchi G, Francolini G, Detti B, Mariotti M, Salvestrini V, Garlatti P, **Aquilano M**, Ciccone L.P, Barberio M, Bruni A, Triggiani L, Guerini A.E., Mazzola R., Cuccia F, Borghesi S, Ingrosso G, Bellavita R, Aristei C, Desideri I, Livi L. Dose escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting, a retrospective study (Oral Communications CO059) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Salvestrini V, Mariotti M, Francolini G, Loi M, Mangoni M, Detti B, Pinzani P, Salvianti F, Desideri I, **Aquilano M**, Garlatti P, Stocchi G, Scoccimarro E, Ciccone L.P, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. Prospective evaluation of biomarkers (ARV7, ARFL AND PSMA) detection on circulating tumor cells of mcrpc patients: preliminary analysis of PRIMERA TRIAL (NCT04188275) (Oral Communications CO097) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Stocchi G, Bonomo P, Desideri I, Salvestrini V, Cerbai C, **Aquilano M**, Scoccimarro E, Teriaca M.A, Gallo O, Santoro R, Spinelli G, Livi L. Quality of life: an interim analysis of patients with locally advanced squamous cell carcinoma of the head and neck treated with durvalumab plus cetuximab and radiotherapy in the phase I/II PHASE trial (NCT03051906) (Poster 081) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Scoccimarro E, **Aquilano M**, Cerbai C, Bonomo P, Desideri I, Teriaca M.A, Maragna V, Stocchi G, Livi L. Pilot prospective assessment of patient reported taste alterations in head and neck cancer: predictive impact of dose distribution to the mobile tongue (Poster 083) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Aquilano M, Scoccimarro E, Cerbai C, Teriaca M.A., Maragna V, Izzo M, Barberio M, Desideri I, Bonomo P, Livi L. Preliminary results of quality of life and skin toxicity in head and neck cancer using EORTC QLQ-C30, QLQ-H&N43 questionnaires and SKINDEX 29 (Poster 086) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Cerbai C, Scoccimarro E, **Aquilano M**, Teriaca M.A, Lucidi S, Bellini C, Pancani S, Alpignano G, Rami J, Bonomo P, Desideri I, Livi L. Pilot assessment of glim criteria in head and neck cancer: predictive ability of weight loss at the end of chemo-radiotherapy (Poster 087) RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020 XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Ganovelli M, Maragna V, Teriaca M.A, Caramia G, Cerbai C, **Aquilano M** Radiotherapy management of glioblastoma (gbm) during covid 19 pandemic: practical vademecum of the available evidence. (Poster 336 RADIOTERAPIA PERSONALIZZATA: UN NUOVO PARADIGMA IN ONCOLOGIA - Virtual - 9-12 Dicembre 2020) XXX CONGRESSO NAZIONALE AIRO- XXXII CONGRESSO NAZIONALE AIRB- XI CONGRESSO NAZIONALE AIRO GIOVANI

Aquilano M, Russo M.L, Carfagno T, Croci S, Santini S, Stefanacci M, Fondelli S, Barca S, Alpi P, Ingrosso G, Bottero M, Ali E, Borghesi S, Caramia G, Francolini G, Detti B, Livi L. Evaluation of prognostic factors in prostate cancer patients with post prostatectomy biochemical relapse and re-staged with choline PET/CT: a multicentric retrospective series (Oral Communications CO002) XXIX Congresso AIRO 2019 "L'INNOVAZIONE IN RADIOTERAPIA E IN ONCOLOGIA CLINICA: UN PONTE VERSO IL FUTURO" - Rimini, 27-29 settembre 2019

Ciccione L.P, Scoccimarro E, **Aquilano M**, Garlatti P, Perna M, Francolini G, Desideri I, Simontacchi G, Detti B, Livi L. Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a single center retrospective analysis (Discussed Poster DP12) XXIX Congresso AIRO 2019 "L'INNOVAZIONE IN RADIOTERAPIA E IN ONCOLOGIA CLINICA: UN PONTE VERSO IL FUTURO" - Rimini, 27-29 settembre 2019

Lucidi S, Ciabatti C, Russo M. Lo, Lorenzetti V, Garlatti P, **Aquilano M**, Becherini C, Meacci F, Desideri I, Scotti V, Meattini I, Livi L. Triple-negative breast cancer: an observational , monocentric, retrospective analysis (Poster PO045) XXIX Congresso AIRO 2019 "L'INNOVAZIONE IN RADIOTERAPIA E IN ONCOLOGIA CLINICA: UN PONTE VERSO IL FUTURO" - Rimini, 27-29 settembre 2019

MOTHER LANGUAGE **ITALIAN**

Other language(s)

Self-assessment

European level (*)

English

| Understanding | | Speaking | | Writing | |
|---------------|---------|--------------------|-------------------|---------|--|
| Listening | Reading | Spoken interaction | Spoken production | | |
| B2 | B2 | B2 | B2 | B2 | |

(*) [Common European Framework of Reference for Languages](#)


Social skills and competences

Working relationship and communication related to the role of doctor in training, with adaptability and availability in each even critical situations.

Computer skills and competences

Software Microsoft Office (Word, Excel, PowerPoint): excellent
Basic statistical analysis (MEDCALC)
Windows e OSX: excellent

I authorize the use of my personal data in accordance with Legal Decree 30 June 2003, No 196 "Protection of personal data" and I assure that the reported information is true



Olbia, 12/08/2022